Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19937708 | 0.82 | RAB9A (0.46) | SMN1; SMN2RAB9ANPC1TRPM8TDP1 | |
| SCHEMBL28109155 | 0.80 | PARP15 (0.43) | SMN1; SMN2RAB9ANPC1TRPM8TDP1 | |
| SCHEMBL19475116 | 0.78 | RAB9A (0.40) | SMN1; SMN2RAB9ANPC1TRPM8ALDH1A1 | |
| SCHEMBL16887640 | 0.77 | RAB9A (0.40) | SMN1; SMN2RAB9ANPC1TRPM8TDP1 | |
| SCHEMBL5540669 | 0.76 | RAB9A (0.54) | SMN1; SMN2RAB9ANPC1TRPM8TDP1 | |
| SCHEMBL16892250 | 0.76 | — | — | |
| SCHEMBL874465 | 0.74 | — | — | |
| SCHEMBL2660240 | 0.73 | KDM4E (0.44) | SMN1; SMN2RAB9ANPC1TRPM8MEN1 | |
| SCHEMBL28488682 | 0.73 | MGAM (0.44) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL18696308 | 0.73 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1TRPM8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| CN-100467440-C | Quaternary bis-ammonium salt precursors and their uses as prodrugs having an antiparasitic activity | CENTRE NAT RECH SCIENT (FR) | 2009-03-11 | — | — | CN | disclosed |
| CN-1956971-A | Novel fused heterocycles and application thereof | ASTRAZENECA AB (SE) | 2007-05-02 | — | — | CN | disclosed |
| CN-1733699-A | Quaternary bis-ammonium salt precursors and their uses as prodrugs having an antiparasitic activity | CENTRE NAT RECH SCIENT (FR) | 2006-02-15 | — | — | CN | disclosed |
| WO-2005095391-A1 | THIAZOLIUMS AS TRANSKETOLASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| CN-1181043-C | Bis-quaternary ammonium salt precursors and their use as antiparasitic prodrugs | ���ҿ�ѧ�о����� | 2004-12-22 | — | — | CN | disclosed |
| CN-1372539-A | Bis-quaternary ammonium salt precursors and their use as antiparasitic prodrugs | CT NAT DE LA RECH SCIENT C N P (FR) | 2002-10-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | TKT, RRM2, TYMS | SMN1; SMN2 3605/4885RAB9A 1148/4885NPC1 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.